Jack is responsible for the Company�s financial and administrative activities, including interaction with capital markets and investor relations. As a member of the company�s senior management and Pharmaceutical Leadership Team, he will play a key role in shaping corporate strategy. Importantly, in his role as CFO, Jack will help to assure that the Company has the necessary economic resources to realize its vision for its pipeline of three late stage clinical development assets, which is critical to create profitable growth and shareholder value.



Jack has over 18 years of public and private company experience and more than a decade of audit, tax, and SEC registrant experience with a major audit firm. He was most recently Senior Vice President and Chief Financial and Accounting Officer at Corautus Genetics Inc. where he was responsible for all areas in finance, accounting, treasury, risk management, and administration for Corautus, which was publicly traded on NASDAQ. Mr. Callicutt joined Corautus in September 2003 and during his tenure completed several private placements and convertible debt offerings totaling over $50 million. He also negotiated and closed the recent merger of Corautus with Via Pharmaceuticals, Inc.



Prior to joining Corautus Genetics, Mr. Callicutt spent 14 years with Deloitte, a global accounting firm, the last six years as an audit senior manager.

Jack is a Certified Public Accountant and graduated, cum laude, from Delta State University.



Jack also serves as a volunteer at the Atlanta Community Food Bank, Habitat for Humanity, and is on the Advisory Board of Holy Redeemer Catholic School and a member of its finance committee.